Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3' untranslated region (3'UTR) of the DNA methyltransferase 1 (DNMT1) messenger RNA is a critical regulatory segment that controls the expression of the DNMT1 enzyme. DNMT1 is the primary enzyme responsible for maintaining DNA methylation patterns during cell division, ensuring the inheritance of epigenetic marks (UniProt P26358). Dysregulation of DNMT1 is a hallmark of many cancers, where overexpression leads to the silencing of tumor suppressor genes through promoter hypermethylation. The 3'UTR contains binding sites for various microRNAs, such as the miR-148 family, which naturally regulate DNMT1 levels (Braconi et al., 2010). Therapeutic strategies have utilized antisense oligonucleotides (ASOs), such as MG98, to specifically bind this region and trigger mRNA degradation. This reduction in DNMT1 protein levels facilitates the reversal of epigenetic silencing, potentially restoring the expression of tumor suppressors. Clinical studies of MG98 have explored its efficacy in solid tumors and hematological malignancies (Stewart et al., 2003). However, targeting this region presents challenges, including the risk of global DNA hypomethylation and subsequent genomic instability. Despite these challenges, the DNMT1 mRNA 3'UTR remains a significant target for precision epigenetic therapy.
Antisense oligonucleotides or microRNAs bind to the 3'UTR of DNMT1 mRNA to induce its degradation or inhibit its translation, thereby reducing DNMT1 protein levels and reversing aberrant DNA hypermethylation (Stewart et al., 2003; Braconi et al., 2010).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (cytosine-5)-methyltransferase 1 mRNA 3' untranslated region (DNMT1 mRNA 3'UTR) (DNMT1 mRNA 3'UTR).